Cargando…

A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands

BACKGROUND: To assess treatment persistence and adherence in men ≥45 years of age with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), using prescription records from the Netherlands IMS Lifelink™ LRx database. METHODS: In this retrospective, observational coh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Drake, Marcus J., Bowditch, Sally, Arbe, Emilio, Hakimi, Zalmai, Guelfucci, Florent, Amri, Ikbel, Nazir, Jameel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440896/ https://www.ncbi.nlm.nih.gov/pubmed/28532455 http://dx.doi.org/10.1186/s12894-017-0226-2

Ejemplares similares

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
por: Nazir, Jameel, et al.
Publicado: (2017)

A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain
por: Nazir, Jameel, et al.
Publicado: (2018)

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK
por: Hakimi, Zalmai, et al.
Publicado: (2018)

Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review
por: Yeowell, Gillian, et al.
Publicado: (2018)

The Role of Combination Therapy with α-Blockers and Hexanic Extract of Serenoa repens in the Treatment of LUTS/BPH
por: De Nunzio, Cosimo, et al.
Publicado: (2022)

PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH
por: Gacci, M., et al.
Publicado: (2013)

Current consensus and controversies on male LUTS/BPH (part one)
por: Foo, Keong Tatt
Publicado: (2017)

Current consensus and controversies on male LUTS/BPH (part two)
por: Foo, Keong Tatt
Publicado: (2018)

Moving beyond BPH – A contemporary update on male LUTS
por: Chapple, Christopher R.
Publicado: (2019)

Tadalafil Alone or in Combination with Tamsulosin for the Management for LUTS/BPH and ED
por: Sebastianelli, A., et al.
Publicado: (2020)

Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil
por: Park, Hyun Jun, et al.
Publicado: (2013)

AB201. Two birds with one stone: α-blocker therapy on LUTS/BPH in men concomitant with mild hypertension
por: Xiao, Hengjun, et al.
Publicado: (2016)

A retrospective analysis comparing persistence and adherence to treatment with free‐ vs fixed‐dose combination of an alpha blocker and an antimuscarinic agent in men with LUTS in Spain
por: Landeira, Margarita, et al.
Publicado: (2020)

Clinically Meaningful Improvements in LUTS/BPH Severity in Men Treated with Silodosin Plus Hexanic Extract of Serenoa Repens or Silodosin Alone
por: Boeri, Luca, et al.
Publicado: (2017)

L.I.F.T. study: Prostatic urethral lift for the treatment of LUTS associated with BPH
por: Gupta, Saurabh
Publicado: (2014)

Current drug therapy of patients with BPH-LUTS with the special emphasis on PDE5 inhibitors
por: Kolontarev, Konstantin, et al.
Publicado: (2016)

Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH
por: Roehrborn, C G, et al.
Publicado: (2011)

Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH – a double-blind randomized trial
por: Manohar, Chikka Moga Siddaiah, et al.
Publicado: (2017)

Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients
por: Alcaraz, Antonio, et al.
Publicado: (2021)

LUTS/BPH and SARS-COV2: when a misunderstanding in the correct physiopathology results in incorrect associations
por: De Nunzio, Cosimo, et al.
Publicado: (2021)

Detection of Prostatic Inflammation From Peripheral Lymphocyte Count and Free/Total PSA Ratio in Men With LUTS/BPH
por: Liao, Xinyang, et al.
Publicado: (2020)

Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect Comparison
por: Hakimi, Zalmai, et al.
Publicado: (2020)

WS PRO 160 I 120 mg (a combination of sabal and urtica extract) in patients with LUTS related to BPH
por: Kirschner-Hermanns, Ruth, et al.
Publicado: (2019)

Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression
por: D’Agate, Salvatore, et al.
Publicado: (2020)

Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia
por: Nazir, Jameel, et al.
Publicado: (2015)

Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH
por: Wang, Xing-Huan, et al.
Publicado: (2015)

Cluster analysis of men undergoing surgery for BPH/LUTS reveals prominent roles of both bladder outlet obstruction and diminished bladder contractility
por: Schneider, Andrew J., et al.
Publicado: (2021)

Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder
por: Desroziers, Katia, et al.
Publicado: (2013)

Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials
por: Astermark, Jan, et al.
Publicado: (2021)

PRISMA-combined α-blockers and antimuscarinics for ureteral stent-related symptoms: A meta-analysis
por: Zhang, Yu-ming, et al.
Publicado: (2017)

Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers
por: Chapman, Kenneth R., et al.
Publicado: (2021)

Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH
por: D’Agate, Salvatore, et al.
Publicado: (2019)

Use of Antimuscarinics in the Elderly
por: Patel, Bhavin, et al.
Publicado: (2009)

Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of Serenoa repens versus Tamsulosin Plus 5-Alpha-Reductase Inhibitors for Moderate-to-Severe LUTS-BPH Patients: Results of a Paired Matched Clinical Study
por: Alcaraz, Antonio, et al.
Publicado: (2022)

Prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) in China: results from the China Health and Retirement Longitudinal Study
por: Zhang, Weiyu, et al.
Publicado: (2019)

Clinical Benefit of Tamsulosin and the Hexanic Extract of Serenoa Repens, in Combination or as Monotherapy, in Patients with Moderate/Severe LUTS-BPH: A Subset Analysis of the QUALIPROST Study
por: Alcaraz, Antonio, et al.
Publicado: (2020)

The EXPANDER-1 trial: introduction of the novel Urocross™ Expander System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH)
por: Woo, Henry H., et al.
Publicado: (2022)

Complications of cataract surgery in patients with BPH treated with alpha 1A-blockers
por: Jan Teper, Slawomir, et al.
Publicado: (2011)

Improvement in pain-related quality of life in patients with hemophilia A treated with rFVIIIFc individualized prophylaxis: post hoc analysis from the A-LONG study
por: Pasi, John, et al.
Publicado: (2022)

Elicitation of Health-related Quality-of-life Concepts Associated with Overactive Bladder: A Qualitative Study
por: Hawken, Natalia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_i0l5948636koj6vna33hbraa45